Use of leptin antagonists for the treatment of diabetes

The use of an antagonist of leptin for the manufacture of a medicament for the treatment of insulin resistance.

A method for the treatment of disorders resulting from deficiencies in insulin secretion and of hyperglycaemia, in a human or non-human mammal, which method comprises the administration to human or non-human mammal in need of such treatment, an effective, pharmaceutically acceptable, non-toxic amount of an antagonist of leptin.

A method for the treatment of insulin resistance, which method comprises the administration to human or non-human mammal in need of such treatment, an effective, pharmaceutically acceptable, non-toxic amount of an antagonist of leptin.

A pharmaceutical composition for the treatment of disorders resulting from deficiencies in insulin secretion and of hyperglycaemia, comprising an antagonist of leptin, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

A pharmaceutical composition for the treatment of insulin resistance, comprising an antagonist of leptin, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.